CytoSorbents Corporation announced on September 23, 2026, that it has regained compliance with a key listing requirement of the Nasdaq Stock Market. The company received confirmation from Nasdaq on September 22, 2026, that it is no longer in violation of Nasdaq Listing Rule 5550(a)(2). This rule requires a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market.
According to the notification, the company achieved compliance because the closing bid price of its common stock was $1.00 or greater for 10 consecutive trading sessions ending September 21, 2026. As a result, Nasdaq has determined that the matter regarding the minimum bid price is now closed.
Despite resolving the bid price issue, the company remains subject to another Nasdaq listing standard. On June 29, 2026, CytoSorbents received notice that it was not in compliance with Nasdaq Listing Rule 5550(b)(2) because the market value of its listed securities fell below the $35 million threshold required for continued listing. To regain compliance with this specific requirement, the market value must equal or exceed $35 million for a minimum of 10 consecutive business days.
The company was granted an initial compliance period of 180 calendar days, which was set to expire on December 28, 2026. Management stated that it is evaluating potential actions to regain compliance with the market value requirement and intends to monitor the market value of its listed securities. The company noted that it may consider other options to regain compliance, including increasing stockholders' equity to at least $2.5 million. If the company does not achieve compliance by December 28, 2026, it will receive written notification that its securities are subject to delisting.
CEO Dr. Phillip Chan emphasized that the company is working to address the market value requirement before the deadline. Chan also highlighted the company's focus on executing core business objectives, including driving sales of its CytoSorb product, achieving operating cash flow breakeven in the second half of 2026, and advancing the DrugSorb-ATR system toward FDA regulatory approval.
